Ventis Pharma

What Ventis Pharma does

Ventis Pharma Corporation is a private biopharmaceutical company founded in 2017 by CEO Tim Patrick and headquartered in Newport Beach, California. The company develops pain management therapies centered on proprietary long-acting local anesthetic formulations, with marketed products including Enduracaine™, Endura-KT™, and Sedare™ (a nasal spray product line in development). Its core technology platform is a local anesthetic formulation protected by a patent portfolio spanning more than 40 countries, with regulatory pursuit of FDA fast-track approval for Enduracaine as a key catalyst.

The company's go-to-market operates on a hybrid model. Commercial sales of compounded preparations are routed through FDA 503B outsourcing facilities and distributed to healthcare providers across multiple verticals — dental/oral and maxillofacial surgery, emergency medicine, orthopedics, and ambulatory surgery centers (e.g., Dune Surgical Hospital). In parallel, Ventis is pursuing indication expansion and geographic reach through development partnerships: a 2025-10-31 partnership with STAQ Pharma and a separate partnership with Danish biotech Cessatech target pediatric pain management via the CT001 program, opening an entirely new customer segment of pediatric hospitals and prescribers.

Operationally, Ventis runs a lean organization of 11-50 employees and has recently formalized a dedicated Dental Division with new leadership (Bettina Cantrell as President, Jamie Cantrell as Operations Manager), indicating a vertical-specific commercialization motion alongside the broader hospital and surgical channel. No revenue, ARR, or funding history is disclosed in the available data, leaving the company's commercial scale and capital position as open questions.

Name

Ventis Pharma

Legal name

Ventis Pharma Corporation

Website

https://ventispharma.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Ventis Pharma is a private biopharmaceutical company developing long-acting local anesthetic pain management therapies (Enduracaine™, Endura-KT™, Sedare™) for dental, emergency medicine, orthopedic, and pediatric healthcare providers, with US commercialization via FDA 503B compounding and development partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

Newport Beach

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of compounded pharmaceutical preparations including Endura-KT and Enduracaine to licensed healthcare professionals. Products are sold per-order for office use by physicians, surgeons, and dental practitioners.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Ventis Pharma develops and sells compounded local anesthetic pain management formulations, led by Enduracaine (an ultra-long-acting, low-toxicity combination of lidocaine, tetracaine, and epinephrine) and Endura-KT, an opioid-free, preservative-free local anesthetic for post-operative pain relief. Products are produced in FDA-registered 503B Outsourcing Facilities under cGMP and sold per-order to licensed healthcare professionals including physicians, surgeons, anesthesiologists, and dental practitioners.

Product overview

Ventis Pharma is a biopharmaceutical company developing a portfolio of pain management products. The core product line is led by Enduracaine™, an ultra-long-acting, low-toxicity local anesthetic formulation. The company also markets Endura-KT™ (an FDA 503B compounded opioid-free local anesthetic) and Sedare™ (a needle-free sufentanil-ketamine nasal spray). An intermediate 503B version of Enduracaine™ addresses immediate clinical needs while the fully optimized formulation advances through FDA fast-track approval. A low-dose oral analgesic for dental applications is in the pipeline. The company also maintains a Dental Division offering compounded preparations under Section 503B of the Federal Food, Drug, and Cosmetic Act.

Differentiator

Problem solved

Functional benefit

Brands

• Dental Division: A dedicated division focused on offering products that meet the clinical needs of oral and maxillofacial practitioners seeking consistent quality and dependable performance, operating under Section 503B of the Federal Food, Drug, and Cosmetic Act.

Products and services

• Enduracaine™ An ultra-long-acting, low-toxicity local anesthetic combining 0.4% lidocaine, 0.2% tetracaine, and 4 mcg/mL epinephrine, designed to transform post-operative pain management as an alternative to opioids and bupivacaine-based products. It is targeted at physicians, surgeons, anesthesiologists, and other licensed healthcare professionals for use in surgical and post-procedural settings.
• Endura-KT™ An opioid-free, preservative-free local anesthetic compound combining lidocaine, tetracaine, and epinephrine for post-operative pain relief. It is produced under FDA 503B compounding standards and marketed for procedural use in oral, dental, and surgical settings by licensed healthcare professionals, including oral and maxillofacial practitioners, emergency room physicians, and orthopedic surgeons.
• Sedare™ A needle-free 503B compounded nasal spray containing sufentanil and ketamine, designed for supervised procedural use in controlled clinical environments where rapid onset and short procedural duration are desired. The product is targeted at licensed healthcare professionals for procedural analgesia.
• Enduracaine™ (503B intermediate formulation) An intermediate FDA 503B compounded iteration of Enduracaine™ introduced to meet immediate clinical needs while the fully optimized Enduracaine formulation advances through FDA fast-track approval. Produced under cGMP standards in an FDA-registered 503B Outsourcing Facility for office use by licensed healthcare professionals.
• Low-dose oral analgesic (dental arena) A low-dose oral analgesic under development to expand Ventis Pharma's pain management portfolio in the dental arena, complementing the company's injectable anesthetic products. Targeted at dental practitioners for procedural and post-procedural pain management.

Quantifiable outcome

• Extended duration anesthetic effect suitable for surgical and post-procedural settings
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• STAQ PharmacoreStrategic or Co-development Partner · 31 October 2025Collaboration with STAQ Pharma for US hospital market entry of CT001 pediatric pain management drug. STAQ Pharma serves as manufacturing partner completing development batches and stability studies for the product. The partnership involves technology transfer for pediatric acute pain treatment targeting US hospitals.
• CessatechcoreStrategic or Co-development PartnerCollaboration with Cessatech, a Danish pediatric biotech company, to bring CT001 pediatric pain management drug to market. Ventis Pharma is collaborating alongside STAQ Pharma to support EMA PUMA pathway evaluation and US hospital launch preparations.
• Weinberg GroupminorImplementation/ SI/ Consulting PartnerFDA consulting partnership with Weinberg Group in Washington DC for regulatory guidance and product development support.
• Straumann GroupminorChannel Partner/ Reseller/ DistributorBettina Cantrell, President of Dental Division, previously held Senior Director of Strategic Accounts role at Straumann Group (ClearCorrect) focusing on Dental Service Organization channel partnerships.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Trevena: Trevena develops acute pain therapeutics including Olinvyk, an IV opioid alternative for hospital use. It addresses the same opioid-sparing hospital pain management opportunity that Ventis targets with Enduracaine.
• Akorn Pharmaceuticals: Akorn is a specialty injectable pharmaceutical company with a relevant local anesthetic portfolio (lidocaine, bupivacaine, tetracaine) overlapping with Ventis's active ingredients and surgical customer base.
• Cumberland Pharmaceuticals: Cumberland is a specialty pharma with hospital-focused products in pain management (including Caldolor IV ibuprofen) and acute care, addressing overlapping hospital and surgical end-customers as Ventis.

Direct peers

• Pacira BioSciences: Pacira commercializes Exparel, a long-acting bupivacaine-based local anesthetic for post-surgical pain. It is the most directly comparable peer because it occupies the same niche (extended-duration local anesthesia) and competes head-to-head for hospital and ASC formulary share that Ventis targets with Enduracaine.
• Innocoll Pharmaceuticals: Innocoll developed Xaracoll, a collagen-matrix bupivacaine implant for postsurgical pain. It is a direct comparable in extended-duration local anesthetic delivery with a similar surgical-pain value proposition.
• Heron Therapeutics: Heron develops sustained-release injectable therapeutics for postoperative pain and CINV, including a bupivacaine product (Zynrelef). Same category of extended-duration local anesthetics, same end-prescribers (surgeons, anesthesiologists), and overlapping procedural pain claims.
• Septodont: Septodont is the leading specialist in dental local anesthetics (articaine, lidocaine, epinephrine combinations). It is the most direct peer to Ventis's Dental Division, competing for the same oral and maxillofacial practitioner customers with Endura-KT.

Broad incumbents

• B. Braun Medical: B. Braun manufactures and distributes a broad portfolio of injectable local anesthetics (including bupivacaine, lidocaine, and ropivacaine) used across hospitals and surgery centers. It competes with Ventis on standard local anesthetics though not in the extended-duration niche.
• Aspen Pharmacare: Aspen manufactures and distributes a global portfolio of injectable anesthetics and analgesics including lidocaine and bupivacaine. Comparable to Ventis as a competing supplier of compounded and branded anesthetic preparations across multiple geographies.
• Pfizer (Hospira injectables): Pfizer's Hospira unit supplies generic injectable local anesthetics (bupivacaine, lidocaine) widely used in US hospitals and ASCs. A broad incumbent rather than a niche extended-duration specialist, but a primary competitor on standard-of-care anesthesia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ventis-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventis Pharma